B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in people with B-cell cancers like lymphoma that have not responded to prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. About 215 adults will take part, and those who benef…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 26, 2026 11:20 UTC
-
New combo therapy aims to keep lymphoma in check longer
Disease control Not yet recruitingThis study looks at whether taking zanubrutinib (a targeted drug) after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults who have already had or are about to have CAR-T therapy will take zanubrutinib as a maintenance treatment. The ma…
Matched conditions: B-CELL LYMPHOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 11:17 UTC
-
Engineered immune cells take on Hard-to-Treat leukemia and lymphoma
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to target and kill cancer cells. It is for adults with leukemia or lymphoma that has come back or not responded to standard therapy. The goal is to see if the treatment is safe and can shrink tumors.
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated May 26, 2026 11:09 UTC
-
New hope for Tough-to-Treat blood cancers: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new drug, NX-5948, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. About 620 adults whose cancer progressed after a previous BTK inhibitor…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Double-Pronged CAR t cells take on tough blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B-cell leukemia or lymphoma who have run out of standard treatments, including commercial CAR T cells. The main goal is to check safety a…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated May 01, 2026 15:57 UTC